FGFR2 and intrahepatic cholangiocarcinoma: Thus, FGFR2 inhibition potently attenuates glucose metabolism in vivo, sensitizing FGFR2 + ICC xenografts to a dual reduction in glucose availability and in OXPHOS activity.